Hepatocellular Carcinoma (HCC) | Norton Healthcare

Indication: Hepatocellular Carcinoma (HCC)

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)

Sub-indication: Gastrointestinal Cancer

Study Type: Drug Study

Principal Investigator: Robert Martin, M.D., Ph.D.
University of Louisville Physicians - Surgical Oncology

Sponsor: Sponsor: Merck Sharp & Dohme CORP

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.